Latest Acromegaly Stories
Two studies presented at ENDO 2015 contribute to growing body of knowledge about acromegaly treatment NEWTON, Mass. and JERUSALEM, March 5, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
NEWTON, Mass. and JERUSALEM, Feb. 27, 2015 /PRNewswire/ -- Chiasma, Inc., a U.S.
NEWTON, Mass. and JERUSALEM, Feb. 24, 2015 /PRNewswire-USNewswire/ -- Chiasma, Inc., a U.S.
-- Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels(1) -- Signifor LAR, a next-generation somatostatin
ReportsnReports.com adds EpiCast Report Acromegaly and Gigantism Epidemiology Forecast to 2023 to its store.
- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P
-Primary efficacy results on track to be received by end of August 2014 TOORAK, Australia, July 29, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP") is pleased to report
Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality(1,2) EAST HANOVER, N.J., May
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.